Financial Performance - Operating revenue for the first quarter of 2024 was ¥36,133,021.41, representing a significant decrease of 39.14% year-over-year[12] - Net profit attributable to shareholders for the same period was ¥867,778.34, down 92.26% from the previous year[12] - The company's cash flow from operating activities was ¥5,835,664.45, a decrease of 4.04% compared to the previous year[12] - The company's gross profit margin decreased significantly, with operating costs dropping by 36.67% to ¥18,553,192.62, in line with the revenue decline[14] - Other income increased by 178.17% to ¥844,075.19, mainly due to an increase in government subsidies received[14] - The company reported a net loss from investments of ¥18,555.16, a decline of 105.49% due to increased foreign exchange losses[14] - Total operating revenue for Q1 2024 was CNY 36,133,021.41, a decrease from CNY 59,366,785.38 in Q1 2023[41] - The net profit for Q1 2024 was CNY 2,261,665.67, down from CNY 11,811,786.28 in Q1 2023, representing a decline of approximately 81%[46] - The total profit for Q1 2024 was CNY 2,158,883.87, compared to CNY 13,045,983.05 in Q1 2023, indicating a decrease of about 83%[45] - The company's operating profit for Q1 2024 was CNY 2,247,758.72, a significant decrease from CNY 13,034,239.44 in Q1 2023[45] Assets and Liabilities - Total assets as of March 31, 2024, amounted to ¥420,570,852.08, reflecting a slight increase of 0.29% compared to the end of 2023[12] - The total current assets as of March 31, 2024, amount to CNY 153,179,756.16, a slight decrease from CNY 156,540,883.29 as of December 31, 2023[35] - The company's total assets as of March 31, 2024, are CNY 420,570,852.08, compared to CNY 419,349,869.28 at the end of 2023[37] - The total liabilities as of March 31, 2024, stand at CNY 56,085,891.80, an increase from CNY 55,024,474.35 as of December 31, 2023[37] - The company's equity attributable to shareholders as of March 31, 2024, is CNY 362,364,417.33, up from CNY 361,719,164.20 at the end of 2023[37] Shareholder Information - The total number of ordinary shares outstanding remained at 98,071,643, with no changes in the shareholding structure[18] - The top five shareholders hold a combined 72.62% of the company's shares, with Wang Min and Wang Fang owning 25.91% and 19.43% respectively[21] - The total number of shares held by the top ten shareholders is 71,223,533, with 42,004,090 shares subject to restrictions[21] - The company has no pledged or judicially frozen shares among its major shareholders[22] Stock Incentive Plan - The company approved a stock incentive plan in 2022, granting 675,000 restricted shares and 805,000 stock options to 58 key employees[26] - As of December 2022, the company granted an additional 140,000 stock options to 9 core employees under the stock incentive plan[27] - The company plans to repurchase and cancel 62,700 restricted shares and 137,000 stock options due to non-compliance with performance assessments[27] - The company plans to cancel 14,000 stock options from two core employees who have left the company as part of the 2022 equity incentive plan[28] - The company has canceled 151,000 stock options from nine employees due to performance criteria not being met[28] - As of March 31, 2024, the company has granted a total of 675,000 restricted shares and 945,000 stock options under the 2022 equity incentive plan[28] Cash Flow and Investments - The company's cash and cash equivalents increased by 39.11% to ¥57,115,052.36, primarily due to the redemption of maturing financial products[13] - The company reported a decrease in cash and cash equivalents from CNY 57,115,052.36 on December 31, 2023, to CNY 41,056,044.29 on March 31, 2024[35] - The net cash flow from investing activities was 10,688,251.37 CNY for the current period, compared to 13,562,348.45 CNY in the previous period, reflecting a decrease of approximately 21%[48] - The net cash flow from operating activities was 7,872,044.34 CNY, an increase from 4,183,283.04 CNY year-over-year, representing an increase of approximately 88%[49] - The cash inflow from investment recovery was 42,000,000.00 CNY, down from 105,000,000.00 CNY, reflecting a decrease of approximately 60%[49] - The cash flow from financing activities resulted in a net outflow of -456,468.24 CNY, slightly worse than the previous period's net outflow of -426,295.98 CNY[48] Market Outlook and Risks - The company anticipates a challenging market environment ahead, with potential impacts from regulatory changes affecting sales[7] - There are no ongoing litigation or arbitration matters affecting the company[24] - The company has not provided any external guarantees or loans during the reporting period[24] - The company has fulfilled its commitments regarding the public issuance of shares to qualified investors[24] - The company has not disclosed any new commitments during the reporting period[29] - The company has not conducted an audit for the financial report[33]
锦好医疗(872925) - 2024 Q1 - 季度财报